New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows

First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.

  News   Nov 27, 2025   0   16  Add to Reading List
New drug combo nearly doubles survival for BRAF-mutated lung cancer patients, trial shows
Why the Hen Does Not Have Teeth Story Book

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

It’s an amazing story, composed out of imagination and rich with lessons. You’ll learn how to be morally upright, avoid immoral things, and understand how words can make or destroy peace and harmony.

Click the image to get your copy!

Why the Hen Does Not Have Teeth Story Book

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

It’s an amazing story, composed out of imagination and rich with lessons. You’ll learn how to be morally upright, avoid immoral things, and understand how words can make or destroy peace and harmony.

Click the image to get your copy!

Why the Hen Does Not Have Teeth Story Book

WHY THE HEN DOES NOT HAVE TEETH STORY BOOK

It’s an amazing story, composed out of imagination and rich with lessons. You’ll learn how to be morally upright, avoid immoral things, and understand how words can make or destroy peace and harmony.

Click the image to get your copy!

A woman works on a lung cancer vaccine on October 1, 2023 at the Ose Immunotherapeutics laboratory in Nantes. (photo credit: LOIC VENANCE/AFP via Getty Images)
First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow